This is a routine preclinical update for a micro-cap biotech. The positive toxicokinetic data is a modest pipeline de-risking step but does not change the company's fundamental risk profile. Monitor for initiation of GLP toxicology studies and eventual IND filing, which are likely months away.
Price Chart
Executive Summary
MIRA Pharmaceuticals reported positive toxicokinetic findings from a 7-day repeated-dose study of its obesity drug candidate SKNY-1 in Beagle dogs. The data showed rapid oral absorption and dose-dependent systemic exposure, which the company believes de-risks dose selection for planned GLP toxicology studies and IND-enabling development. This is an early-stage preclinical update with no financial data or new revenue-generating milestones, making it a modest positive for the pipeline but not a material catalyst for the stock given the $28M market cap and the company's history of negative post-filing returns.
Key Facts
- SKNY-1 demonstrated rapid oral absorption and dose-dependent systemic exposure in a 7-day Beagle dog study.
- Plasma concentrations were comparable between male and female animals.
- Findings support dose selection for planned GLP toxicology studies and IND-enabling development.
- SKNY-1 is an investigational oral drug candidate for obesity designed to preserve lean body mass.
- The company has a $28M market cap and no revenue from approved products.
Financial Impact
No financial figures reported; preclinical milestone with no immediate revenue impact.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- SKNY-1 is in early development and requires significant additional studies and regulatory approvals.
- The company has a limited cash runway and may need to raise capital to fund further development.
- Historical post-filing returns for MIRA have been negative, indicating poor market reception to similar updates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036262 |
| Exhibit: ex99-1.htm | 0001493152-26-036262 |
| Document: 0001493152-26-036262-index-headers.html | 0001493152-26-036262 |
| Document: 0001493152-26-036262-index.html | 0001493152-26-036262 |
| Document: 0001493152-26-036262.txt | 0001493152-26-036262 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.6290 $0.6195 | ▼ −1.51% | ▼ −0.99% | $0.5500 (−12.56%) |
Oct 22, 2026 5d ago | Press Release | $0.6289 $0.6195 | ▼ −1.49% | ▼ −0.97% | $0.5500 (−12.55%) |
Sep 17, 2026 5w ago | 8-K | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5500 (−27.56%) |
Sep 17, 2026 5w ago | Press Release | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5500 (−27.56%) |
Sep 1, 2026 8w ago | 8-K | $0.8600 $0.8495 | ▼ −1.22% | ▼ −1.66% | $0.5500 (−36.05%) |
Aug 6, 2026 11w ago | 8-K | $0.6782 $0.7400 | ▲ +9.11% | ▲ +8.50% | $0.5500 (−18.90%) |
Jul 10, 2026 15w ago | 8-K | $0.9245 $0.9097 | ▼ −1.60% | ▼ −0.84% | $0.5500 (−40.51%) |
Jul 6, 2026 16w ago | 8-K | $0.9549 $0.9478 | ▼ −0.74% | ▼ −0.27% | $0.5500 (−42.40%) |
Jun 17, 2026 18w ago | 8-K | $0.9782 $0.9524 | ▼ −2.64% | ▼ −3.42% | $0.5500 (−43.77%) |
Jun 8, 2026 20w ago | 8-K | $0.9767 $0.9802 | ▲ +0.36% | ▲ +1.93% | $0.5500 (−43.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers